Developments in the systemic therapy of pancreatic cancer
Related Experiment Video
Updated: Sep 26, 2026
Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
Published on: February 2, 2024
B F el-Rayes1, A F Shields, V Vaitkevicius
1Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, 4100 John R Street, Detroit, MI 48201, USA.
Abstract:
Pancreatic adenocarcinoma is the fourth leading cause of cancer mortality in the United States of America. Progress in the treatment of this disease in the past several decades has been very modest. Several new agents with activity against pancreatic cancer have been identified. Of these, gemcitabine is the most promising agent when used in combination with other drugs. Pilot phase II studies combining gemcitabine with 5-flourouracil, irinotecan, docetaxel, or cisplatin show improved outcomes in objective response rates and survival that need to be confirmed in larger randomized studies. Advancement in the understanding of the molecular biology of neoplasia in recent years has helped identify several molecular targets for future new drug development in pancreatic cancer. Assessment of response to therapy of pancreatic cancer has been a difficult challenge. Functional imaging with techniques such as positron emission tomography (PET) may yield a more precise and timely objective evaluation of response to treatment.
Insights
Pancreatic cancer treatment shows modest progress, with gemcitabine combinations offering promise. Further research is needed to confirm improved response rates and survival, alongside exploring new molecular targets and advanced imaging techniques.
Area of Science:
- Oncology
- Medical Research
Background:
- Pancreatic adenocarcinoma is a leading cause of cancer mortality in the USA.
- Treatment progress for pancreatic cancer has been limited over recent decades.
Purpose of the Study:
- To review current treatment strategies for pancreatic cancer.
- To highlight promising new agents and future research directions.
Main Methods:
- Review of pilot phase II studies combining gemcitabine with other agents (5-fluorouracil, irinotecan, docetaxel, cisplatin).
- Discussion of advancements in understanding pancreatic cancer molecular biology.
- Exploration of functional imaging techniques like positron emission tomography (PET) for response assessment.
Main Results:
- Gemcitabine in combination with other drugs shows potential for improved objective response rates and survival in pilot studies.
- Identification of molecular targets offers avenues for novel drug development.
- Functional imaging may provide more precise evaluation of treatment response.
Conclusions:
- Combination chemotherapy, particularly with gemcitabine, warrants further investigation in larger randomized trials.
- Targeted therapies based on molecular biology advancements are crucial for future treatment strategies.
- Advanced imaging techniques like PET could enhance the assessment of treatment efficacy in pancreatic cancer.
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...